Rheumatoid Arthritis

The Rheumatoid Arthritis pipeline: 79 tracked drugs, 36 approved for this indication.

36 approved / phase 47 Phase 313 Phase 21 Phase 1/216 Phase 16 preclinical / unstaged

Compare the share prices of listed companies in Rheumatoid Arthritis →

Total attributable cost

$13.1B

$9,662/patient

Drug spend

$4.5B

$3,331/patient

How this is calculated ↗

All severities and treatment regimens (US estimate) · US

The Rheumatoid Arthritis pipeline

Key trial results for every approved and late-stage drug: Rheumatoid Arthritis results by drug.

← all assets